Breast Carcinoma
|
0.390 |
Biomarker
|
disease |
BEFREE |
Kaplan-Meier plots suggested that expression of <i>TYMS</i>, tubulin β3 class III (<i>TUBB3</i>) and <i>TOP2A</i> genes was significantly associated with relapse-free survival for ER<sup>+</sup> breast cancer.
|
31186766 |
2019 |
Breast Carcinoma
|
0.390 |
AlteredExpression
|
disease |
BEFREE |
In addition, the interaction of exogenous RILPL2 with TUBB3 resulted in the downregulation of BC cell proliferation and migration and upregulation of PTEN expression by promoting destabilization of TUBB3.
|
31497344 |
2019 |
Breast Carcinoma
|
0.390 |
Biomarker
|
disease |
BEFREE |
The expressions of excision repair cross-complementing-1 (ERCC1), class III beta-tubulin, breast cancer susceptibility gene I (BRCA1), and thymidylate synthase were investigated simultaneously in the pre-treatment endoscopic tumor biopsy samples.
|
27130464 |
2017 |
Breast Carcinoma
|
0.390 |
Biomarker
|
disease |
BEFREE |
This was further substantiated by selective depletion of TUBB3 in a series of breast cancer cell lines expressing high levels of TUBB3.
|
29069726 |
2017 |
Breast Carcinoma
|
0.390 |
GeneticVariation
|
disease |
BEFREE |
We found that the disease-free survival (DFS) and overall survival (OS) of breast cancer patients with TUBB3‑positive tumors were lower than these rates in the patients with TUBB3-negative tumors.
|
28075472 |
2017 |
Breast Carcinoma
|
0.390 |
Biomarker
|
disease |
BEFREE |
TUBB3 knockdown studies were conducted in breast cancer models (MDA-Br, GLIM2, and MDA-MB-468), which revealed significant reduction in their invasive capabilities.
|
25724666 |
2015 |
Breast Carcinoma
|
0.390 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, TUBB3 expression correlated significantly with molecular markers of breast cancer, such as PgR and HER2, suggesting that TUBB3 mRNA level facilitate the identification of a subset of patients who respond to Taxane treatment in addition to hormonal therapy and trastuzumab.
|
26406408 |
2015 |
Breast Carcinoma
|
0.390 |
Biomarker
|
disease |
BEFREE |
The study investigated the clinical significance of RRM1 (ribonucleoside reductase subunit M1), TUBB3 (tubulin-β-III), TOP2A (DNA topoisomerase II), CYP19A1 (cytochrome P450, family 19, subfamily A, polypeptide 1) and CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) for the diagnosis and possible predictive roles in breast cancer.
|
26252353 |
2015 |
Breast Carcinoma
|
0.390 |
GeneticVariation
|
disease |
BEFREE |
Accordingly, we evaluated the predictive efficiency of qRT-PCR and immunohistochemical analysis (IHC) on excision cross complementation group 1 (ERCC1), breast cancer susceptibility gene 1 (BRCA1), ribonucleotide reductase subunit M1 (RRM1) and class III β-tubulin (TUBB3).
|
21996087 |
2012 |
Breast Carcinoma
|
0.390 |
Biomarker
|
disease |
CTD_human |
[The correlation between chemotherapeutic efficacy and breast cancer susceptibility gene 1 and class IIIβ-tubulin protein expression in non-small cell lung cancer patients].
|
21781528 |
2011 |